Imunon, Inc. (IMNN) NASDAQ
2.14
-0.01(-0.47%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.14
-0.01(-0.47%)
Currency In USD
Address
997 Lenox Drive
Lawrenceville, NJ 08648
United States of America (the)
Phone
609 896 9100
Website
Sector
Healthcare
Industry
Biotechnology
Employees
25
First IPO Date
March 01, 1999
| Name | Title | Pay | Year Born |
| Stacy R. Lindborg | President, Chief Executive Officer & Director | 925,349 | 1971 |
| Timothy J. Tumminello | Chief Accounting Officer & Controller | 108,308 | 1958 |
| Douglas V. Faller | Chief Medical Officer | 559,462 | 1953 |
| Michael H. Tardugno | Executive Chairman | 571,225 | 1951 |
| Jeffrey W. Church | Interim Chief Financial Officer | 798,171 | 1957 |
| Kristin Longobardi | Senior Vice President of Strategic Operations | 0 | N/A |
| Susan Mary Eylward | General Counsel & Corporate Secretary | 0 | 1980 |
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.